Roche and Merck Navigate Tariff Headwinds as NEJM Faces U.S. Attorney Inquiry
Roche and Merck face tariff challenges, while the New England Journal of Medicine (NEJM) is under scrutiny from a U.S. Attorney. These are the key developments emerging in the pharmaceutical industry today. Specifically, both Roche and Merck are reportedly grappling with issues related to tariffs, impacting their business operations. Separately, the NEJM is fielding inquiries from a U.S. Attorney, the reason for which was not stated.
Newsflash | Powered by GeneOnline AI
Date: April 24, 2025
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20